6,240 results match your criteria Bulletin Du Cancer[Journal]


[Time perspective and quality of life in rectal cancer patients: An exploratory study].

Bull Cancer 2019 Apr 19. Epub 2019 Apr 19.

Université Bordeaux, laboratoire handicap, activité, cognition, santé, EA 4136, 33076 Bordeaux cedex, France.

The impact of rectal cancer on patient quality of life has been investigated but no research has yet examined the impact of time perspective in the assessment of quality of life of rectal cancer patients. Our goal is to explore the links between quality of life and time perspective and the role of time perspective as a determinant of quality of life. Data were collected from 69 patients who completed a questionnaire comprising a specific measure of quality of life (FACT-C), a measure of time perspective (ZTPI), a measure of emotional distress (HADS) and a collection of socio-demographic and medical data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.03.002DOI Listing

[Related donors follow-up: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bull Cancer 2019 Apr 18. Epub 2019 Apr 18.

Agence de la Biomédecine, pôle stratégie prélèvements greffes CSH, direction prélèvements/greffes CSH, direction générale médicale et scientifique, 1, avenue du Stade-de-France, 93212 Saint-Denis-la-Plaine cedex, France.

Since 2010 there has been an exponential increase of the number of transplants performed from related donors. The development of haploidentical transplants increases the resort to related-donation, which presents two main advantages: a less important financial cost and a faster availability of the graft. Standards for mandatory accreditation exist, but the adherence to these recommendations is not optimal: currently, different practices regarding the organizational modalities of care, recruitment criteria, qualification and follow-up of related donors have been observed among French transplant centers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.006DOI Listing

[Osteopathy for chronic pain after breast cancer surgery: A monocentric randomised study].

Bull Cancer 2019 Apr 17. Epub 2019 Apr 17.

Centre Léon-Bérard, direction de la recherche clinique et de l'innovation, 28, rue Laennec, 69373 Lyon, France.

Twenty-five to 65% of patients suffer from chronic pain after breast cancer. The treatment combines analgesic drugs and psychophysical techniques.

Hypothesis: Osteopathy improves the control of pain and the quality of life of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.03.005DOI Listing

[Cancer screening words].

Bull Cancer 2019 Apr 16. Epub 2019 Apr 16.

Université de Lille, faculté de médecine Henri-Warembourg, 2, avenue Eugène-Avinée, 59120 Loos, France; Centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France. Electronic address:

Screening (secondary prevention) is a public health action aimed at identifying diseases at their earliest stages, before the onset of signs and symptoms and, thus, avoiding or mitigating their negative consequences. The abnormality can be a genetic defect, an infection or the preclinical phase of a chronic disease such as cancer. We discuss elements common to the cancer screening debate: vocabulary about screening, overdiagnosis, and program indication criteria. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193015
Publisher Site
http://dx.doi.org/10.1016/j.bulcan.2019.03.004DOI Listing
April 2019
1 Read

[Children and adolescents discharge guidelines after allogeneic stem cell transplantation for healthcare professionals: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Bull Cancer 2019 Apr 15. Epub 2019 Apr 15.

Hôpital Robert-Debré, département d'hémato-immunologie pédiatrique, 48, boulevard Serurier, 75019 Paris, France; Université Paris 7-Paris Diderot, 5, rue Thomas-Mann, 75013 Paris, France. Electronic address:

Recommendations for visits or environment restrictions, and sometimes for food are usually well described for inpatient within HSCT unit procedures where those measures are less precise and detailed for outpatient from the discharge to the immune reconstitution achievement. The present paper main objective is to define risk patient groups depending on time, immune-suppressive drugs as well as graft-versus-host disease and immune reconstitution. We define here 3 risk patient groups and propose measures about house cleaning, pets, schools, social activities, hygiene, foods, sexual life and siblings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.03.006DOI Listing

[A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research].

Bull Cancer 2019 Apr 12. Epub 2019 Apr 12.

Institut Curie, université Versailles Saint-Quentin (UVSQ), département d'oncologie médicale, 35, rue Dailly, 92210 Saint-Cloud, France; GERCOR, 151, rue du Faubourg Saint-Antoine, 75011 Paris, France.

Introduction: The demographics of oncology residents has changed since 2010 with the increase in the size of promotions. The evolution of the residents' aspirations towards research and their future exercise in parallel with these demographic changes has not been assessed.

Methods: A questionnaire was developed by a working group from GERCOR (cooperative group in oncology), involving clinicians, researchers, GERCOR members, and residents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.009DOI Listing

[The impact of the patient's age on the delay of the lung cancer treatment].

Bull Cancer 2019 Apr 10. Epub 2019 Apr 10.

CHRU Nancy Site Brabois, département de pneumologie, 9, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France; Université de Lorraine, EA 3450-DevAH, développement, adaptation, handicap, régulations cardio-respiratoire, France. Electronic address:

Introduction: The results from the medical literature regarding the influence of patient's age on the delay of treatment in lung cancer are controversial in the absence of a consensual definition. The aim of this study was to determine the impact of the patient's age on the delay of the lung cancer treatment.

Methods: A retrospective monocentric study was performed including patients treated for a lung cancer in our department between November 1, 2014 and October 31, 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.010DOI Listing
April 2019
1 Read

[How to reconcile therapeutic patient education and care pathology in oncology: Application in head and neck neoplams].

Bull Cancer 2019 Apr 10. Epub 2019 Apr 10.

Centre hospitalier de Valence, unité transversale d'éducation aux patients, 179 boulevard du Maréchal Juin, 26953 Valence, France.

Therapeutic education is an educational approach that allows the patient and his entourage to acquire or maintain the skills necessary to manage their daily lives. It requires a global care of patients and caregivers and is much broader than a learning of technical gesture. While their development is encouraged in the plan cancer 2014-2018, few programs exist in cancer surgery because the process is very cumbersome to implement due to a very strict administrative framework. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.008DOI Listing
April 2019
1 Read

[Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine].

Bull Cancer 2019 Apr 10. Epub 2019 Apr 10.

Centre Antoine-Lacassagne, 06200 Nice, France.

Urothelial carcinoma of the bladder are rare but aggressive tumors with a high metastatic potential. The prognosis of these tumors has not drastically changed over the past 30 years, with an overall survival of less than two years in advanced or metastatic situations. Even though immune checkpoints inhibitors have changed this picture, it is beneficial for less than 30% of patients and there is no reliable biomarkers to identify this specific population of responders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.007DOI Listing

[Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines].

Bull Cancer 2019 Apr 10. Epub 2019 Apr 10.

Hospices Civils de Lyon, Fédération d'endocrinologie, université Claude Bernard Lyon 1, HESPER EA 7425, 69008 Lyon, France.

The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPI). However, the use of ICPI has a risk of side-effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.003DOI Listing

[About the reimbursement of tests predictive of metastatic relapse in operated breast cancers].

Authors:
Jacques Robert

Bull Cancer 2019 Apr;106(4):279-280

Université de Bordeaux, Inserm U 1218, 229, cours de l'Argonne, 33076 Bordeaux cedex, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.03.001DOI Listing

[Hepatobiliary complications following allogeneic hematopoietic cell transplantation: Recommendations of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)].

Bull Cancer 2019 Apr 2. Epub 2019 Apr 2.

Hôtel-Dieu, CHU de Nantes, service d'hématologie clinique, 1, place Ricordeau, 44000 Nantes, France. Electronic address:

Hepatobiliary complications are frequent in the context of allogeneic hematopoietic cell transplantation (allo-HCT) and contribute largely to the morbidity and mortality after transplantation. Within the framework of the ninth workshops of practice harmonization of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held in Lille in September 2018, diagnostic approaches and treatments of hepatobiliary dysfunctions prior to and following transplantation were reviewed according to the analysis of published studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.005DOI Listing
April 2019
1 Read

[Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines].

Bull Cancer 2019 Mar 25. Epub 2019 Mar 25.

Hôpital Foch, département oncologie médicale et soins de support, 40, rue Worth, 92150 Suresnes, France.

Antineoplastic drug induced nausea and vomiting (ANDINV) (previously named: Chemotherapy-induced nausea and vomiting [CINV]) are one of the most feared adverse effect for patients who begin treatment with anti-cancer treatments and their bad control have a negative impact in the management of these patients. In this review article, it is proposed an update of French-speaking Association for oncologic supportive care (AFSOS) clinical practice of CINV guidelines. This update became necessary for several reasons: newly available anti-emetic drugs; new data published about individual risk factors of CINV; new antineoplastic agents available; changing in emetic risk levels for some molecules in the international guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.002DOI Listing
March 2019
1 Read

[Atypical genital development and tumor risk].

Bull Cancer 2019 Mar 22. Epub 2019 Mar 22.

Groupement hospitalier Est, hospices Civils de Lyon, institut Multisite de pathologie, 69500 Bron, France.

Atypical genital development (AGD), also called disorders of sex development are a set of miscellaneous pathologies who have in common a morphological and/or functional abnormality of the internal and/or external genital organs. The Chicago classification identifies 3 major groups based on karyotype, hormone balance and genetic studies. Some AGD predispose to the occurrence of tumors, mainly malignant germ cell tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.018DOI Listing
March 2019
4 Reads

[Testicular germ cell tumors: Histopathological and molecular features].

Bull Cancer 2019 Apr 21;106(4):328-341. Epub 2019 Mar 21.

Hôpital Foch, service d'anatomie et cytologie pathologiques, 40, rue Worth, 92150 Suresnes, France; Institut Curie, service de pathologie, 35, rue Dailly, 92240 Saint Cloud, France. Electronic address:

In 2016, the WHO classification of testicular germ cell tumors was revised considering advances in the understanding of their tumorigenesis and molecular features. This restructuring led to a division into two major groups with, on one hand, prepubertal-type tumors, not derived from germ cell neoplasia in situ (GCNIS), and on the other hand, postpubertal-type tumors, GCNIS-derived, which occur in youg men (seminoma and non seminomatous germ cell tumors - embryonal carcinoma, yolk sac tumor, teratoma and choriocarcinoma essentially). The term germ cell neoplasia in situ is consensually accepted as a new terminology for the precursor lesion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.004DOI Listing
April 2019
1 Read

[Cardiac complications of breast radiation therapy].

Bull Cancer 2019 Apr 21;106(4):379-388. Epub 2019 Mar 21.

Centre de lutte contre le cancer François Baclesse, 3, avenue du Général Harris, 14000 Caen, France; Normandie Université - Unicaen, 14000 Caen, France. Electronic address:

Adjuvant radiation therapy in breast cancer is a standard of care, either post-lumpectomy or in case of lymph node involvement. Internal mammary chain (IMC) is more and more included in the clinical target volume, because it increases overall survival. This increase must be weighed against cardiac complications in left breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.020DOI Listing

[Update regarding the management of vulvar cancer: The guidelines of the Assistance Publique-Hôpitaux de Paris].

Bull Cancer 2019 Apr 18;106(4):371-378. Epub 2019 Mar 18.

AP-HP, hôpital Pitié-Salpêtrière, service de chirurgie et oncologie gynécologique et mammaire, 75013 Paris, France. Electronic address:

Vulvar cancer is a rare disease, which represents 4% of gynecological tumors with an incidence of 0.5 to 1.5 per 100,000 women per year in France. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.017DOI Listing
April 2019
1 Read

[Systematic second opinion review of outside imaging in breast cancer diagnosis: An added value].

Bull Cancer 2019 Apr 15;106(4):316-327. Epub 2019 Mar 15.

Institut de cancérologie de Lorraine, département du Parcours Sein, 54000 Nancy, France.

Introduction: The systematic second opinion review in cancer centers after breast cancer detection is currently under development. The purposes were the evaluation of review's consequences, in particularly of the axillary staging and the evolution of the delays.

Methods: A retrospective study was conducted on patients who consulted a clinician at Cancer Center of Lorraine in Nancy from January 1st, 2016 to December 31th, 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.019DOI Listing
April 2019
1 Read

[Evolution of the regulatory framework in clinical research].

Bull Cancer 2019 Apr 15;106(4):389-394. Epub 2019 Mar 15.

Centre Oscar-Lambret, direction de la recherche clinique et de l'innovation, 3, rue Combemale, 59020 Lille, France; Université Lille-Nord de France, faculté de médecine, place de Verdun, 59000 Lille, France. Electronic address:

The regulatory framework of clinical research is necessary to ensure the protection of participants and to define the actors and their responsibilities. Although main principles have been set up in 1947 with the Nuremberg Code, this regulatory framework is relatively recent in Europe: development of national regulations in the years 1980-1990, first European Directive regarding clinical trials in 2001. In France, as 2006 was marked by the implementation of this first "Clinical trials Directive", the end of the year 2016 and the following months were marked by the enforcement of the Jardé law (previously modified in order to reinforce the regulatory requirements following the death of an healthy volunteer in a clinical trial). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.016DOI Listing

[The practice of management in onco-hematology in Lebanon in 202X: An international model to follow].

Bull Cancer 2019 Apr 14;106(4):281-282. Epub 2019 Mar 14.

Université Saint Esprit de Kaslik, BP 446 Jounieh, Mont Liban, Liban.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.021DOI Listing
April 2019
0.635 Impact Factor

[Diagnostic and treatment pitfalls and guidelines for variants of squamous cell carcinomas of the head and neck: on behalf of the REFCOR].

Bull Cancer 2019 Apr 13;106(4):395-403. Epub 2019 Mar 13.

Hôpital Bichat, département d'oto-rhino-laryngologie (ORL) et chirurgie cervico-faciale, 46 rue Henri-Huchard, 75018 Paris, France.

Among the 20,000 new cases of head and neck neoplasms in France each year, squamous cell carcinomas (HNSCC) represent about 90 % of the cases. Among these, variants of conventional squamous cell carcinomas represent between 5% and 10% of cases. Patient history and risk factors are often similar from those of conventional HSNCC. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193011
Publisher Site
http://dx.doi.org/10.1016/j.bulcan.2019.01.015DOI Listing
April 2019
3 Reads
0.635 Impact Factor

[LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: Ending the controversy for novel guidelines?]

Bull Cancer 2019 Apr 8;106(4):342-353. Epub 2019 Mar 8.

Institut de cancérologie Lucien-Neuwirth, département de la recherche et de l'enseignement (DURE), 108 bis, avenue Albert-Raimond, 42271 Saint-Priest-en-Jarez, France; Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 108 bis, avenue Albert-Raimond, 42271 Saint-Priest-en-Jarez, France. Electronic address:

Endocrine treatment represents the cornerstone of endocrine-sensitive pre-menopausal early breast cancer. The estrogen blockade plays a leading role in the therapeutic management with surgery, radiotherapy and selective antiestrogen treatment. For several years, selective estrogen receptor modulators, such as tamoxifen, have revolutionized medical care of hormone receptors-positive breast cancer and have conquered the therapeutic arsenal while becoming the gold standard of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.012DOI Listing

[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].

Bull Cancer 2019 Apr 6;106(4):354-370. Epub 2019 Mar 6.

AP-HP, institut universitaire de cancérologie Sorbonne université, service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, UMRS-938, 4, rue de La Chine, 75020 Tenon, France.

Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.014DOI Listing
April 2019
3 Reads
0.635 Impact Factor

[5-FU: At last!]

Authors:
Jacques Robert

Bull Cancer 2019 Mar;106(3):173-174

Institut Bergonié, université de Bordeaux, Inserm U916, 229, cours de l'Argonne, 33076 Bordeaux cedex, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.02.001DOI Listing

[Descriptive epidemiology of cancer in metropolitan France: Incidence, survival and prevalence].

Bull Cancer 2019 Mar 2. Epub 2019 Mar 2.

Université Paul-Sabatier, faculté de médecine, réseau des registres de cancers Francim, 37, allée Jules-Guesde, 31073 Toulouse cedex, France.

Introduction: Incidence, mortality, survival and prevalence are key indicators to assess public health policies and estimate the needs of the population for cancer management. The aim of this article is to provide the more current estimates of these indicators, in line with the fifteenth operational objective of the 2014-2019 Cancer Plan "Collect data/Support Public Health".

Methods: Incidence and survival data came from cancer registries. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193006
Publisher Site
http://dx.doi.org/10.1016/j.bulcan.2018.11.016DOI Listing
March 2019
15 Reads

[Non-programmed hospitalization of elderly patients with cancer: Which care pathway?]

Bull Cancer 2019 Apr 1;106(4):293-303. Epub 2019 Mar 1.

CHU La Milétrie, pôle de gériatrie, 2, rue de La Milétrie, 86021 Poitiers cedex, France.

Introduction: Management of elderly patients with cancer is challenging worldwide. Improvement of their care pathway should focus on unplanned hospitalizations. This study aimed to compare the geriatric and oncologic profiles of elderly patients with cancer, hospitalized for an acute pathology either in medical oncology or acute geriatric medicine units. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2018.12.012DOI Listing

Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies.

Bull Cancer 2019 Apr 23;106(4):283-292. Epub 2019 Feb 23.

Hôpital de Meaux, respiratory medicine department, 6-8, rue Saint-Fiacre, BP 218, 77104 Meaux cedex, France.

Background: Although improved during the last decades, the prognosis of lung cancer is poor. In 2000, the French College of general hospital respiratory physicians, conducted KBP-2000-CPHG, a prospective multicenter epidemiological study including all volunteer adult patients diagnosed for primary lung cancer; with the five-year survival as primary endpoint. The primary objective of KBP-2010-CPHG was to compare overall five-year survival data with KBP-2000-CPHG ones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.010DOI Listing

[Lung cancer screening among the smoker population].

Bull Cancer 2019 Feb 15. Epub 2019 Feb 15.

Université Bordeaux, Epicene, centre Inserm U1219, 33000 Bordeaux, France; CHU de Bordeaux, service de médecine du travail et de pathologies professionnelles, 33000 Bordeaux, France.

Context: Lung cancer is the most common cancer in men and the leading cause of cancer death worldwide. This cancer, often diagnosed at an advanced stage, mainly affects smokers and survival could increase with early detection. Screening by chest x-ray has not shown its effectiveness, then several randomized trials have been carried out about screening by thoracic low-dose computed tomography in smokers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2018.12.010DOI Listing
February 2019

[Feedback on a complementary care program combining physical activity, mindfulness-based meditation and socio-aesthetic care].

Bull Cancer 2019 Apr 15;106(4):304-315. Epub 2019 Feb 15.

Gustave-Roussy, unité de psycho-oncologie, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.

Introduction: Increasing physical activity among cancer patients is one of the priority recommendations in tertiary prevention; the level of physical activity is one of the determining factors in reducing the risk of relapse and mortality. However, many barriers to initiation and maintenance of regular physical activity have been identified. A program combining bi-weekly adapted physical activity sessions, mindfulness-based meditation and socio-aesthetic care was put together in 2015, in a Cancer Center, in order to facilitate adherence and sustainable attendance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.013DOI Listing

[Impact of the integration of FIT in the colorectal cancer screening program in France].

Authors:
Guy Launoy

Bull Cancer 2019 Feb 14. Epub 2019 Feb 14.

CHU de Caen, université Caen Normandie, ANTICIPE, U1086 Inserm, Centre Baclesse, avenue Gal-Harris, 14000 Caen, France. Electronic address:

While organized screening for colorectal cancer has been extended to the whole of France since 2008, there is no evidence to suggest that this screening based on use of the guaiac test had a significant impact on trends in its incidence and mortality in France in the last 10 years. Following the first prospective trials conducted in Normandy, FIT (Fecal Immunological Test) was proposed to the entire national territory from 2015. Three years after its generalization, it is of course impossible to measure the effects of this modification of strategy on the incidence or mortality from colorectal cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.011DOI Listing
February 2019

[Complementary and alternative medicine use in two French pediatric oncology centers: A common practice].

Bull Cancer 2019 Mar 14;106(3):189-200. Epub 2019 Feb 14.

CHU de Nantes, service d'onco-hématologie pédiatrique, 44093 Nantes cedex, France. Electronic address:

Background: The use of complementary and alternative medicine (CAM) in children with cancer is commonly used. However, studies and data on this topic are still scarce in France.

Methods: Our aim was to investigate the prevalence of CAM usage in pediatric cancer patients and describe the modality of use. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193006
Publisher Site
http://dx.doi.org/10.1016/j.bulcan.2018.11.017DOI Listing
March 2019
2 Reads
0.635 Impact Factor

[Retrospective study about 20 cases of ovarian Burkitt lymphoma at Yopougon teaching hospital in Côte d'Ivoire].

Bull Cancer 2019 Mar 14;106(3):275-278. Epub 2019 Feb 14.

CHU de Yopougon Abidjan, service d'hématologie, 04 BP 1439, Abidjan 04, Côte d'Ivoire.

Context: The maxillo-facial attack was the first described in the Burkitt lymphoma in 1958 by Denis Pearsons Burkitt. Abdominopelvic disorders, particularly ovarian localization are observed more and more by the developments of imagery technics. Our study aimed to describe the epidemiologic, clinical, therapeutic and evolutive aspects of ovarian localization in the endemic Burkitt lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2018.12.011DOI Listing
March 2019
1 Read

[Circulating tumor DNA assessment for gynaecological cancers management].

Bull Cancer 2019 Mar 11;106(3):237-252. Epub 2019 Feb 11.

Aix-Marseille university, CNRS U7258, Inserm U1068, institut Paoli-Calmettes, département d'oncologie médicale, CRCM, Marseille cedex 9, France; Aix-Marseille university, CNRS U7258, Inserm U1068, institut Paoli-Calmettes, CRCM, laboratoire d'oncologie prédictive, Marseille cedex 9, France. Electronic address:

Gynaecological cancers are frequent, with more than 16,000 cases per year in France for 6500 deaths. Few improvements in diagnostic methods, prognostic tools, and therapeutic strategies have occurred in the last two decades. Tumour genomic analyses from, at least in part, the Cancer Genome Atlas have identified some of the molecular alterations involved in gynaecological tumours growth and spreading. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2018.11.018DOI Listing
March 2019
2 Reads

[MSI Metastatic solid tumors treatment and immunotherapies].

Bull Cancer 2019 Feb 5;106(2):143-150. Epub 2019 Feb 5.

Assistance publique-Hôpitaux de Paris, UPEC, hôpital Henri-Mondor, département d'oncologie médicale, 94010 Créteil, France; Centre hospitalier intercommunal de Créteil, département d'oncologie médicale, 94010 Créteil, France. Electronic address:

Checkpoints inhibitors are known to induce striking tumor responses in advanced MSI colorectal cancers, which used to be related to a poor clinical outcome. The incidence of the MSI phenotype is highly heterogeneous across non-colorectal cancers. The highest incidence rates are found in endometrioid forms of uterine cancers and in gastric tumors (20 to 40 % and 10 to 33 %, respectively). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.008DOI Listing
February 2019
7 Reads

MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.

Bull Cancer 2019 Feb 1;106(2):119-128. Epub 2019 Feb 1.

Centre de recherche Saint-Antoine, Inserm UMR_S 938, équipe "instabilité des microsatellites et cancers", 75012 Paris, France.

Microsatellite instability (MSI), which is caused by deficiency of the DNA mismatch repair (MMR) system, is the molecular abnormality observed in tumors associated with Lynch syndrome. Lynch syndrome represents one of the most frequent conditions of cancer predisposition in human, thus requiring specific care and genetic counseling. Moreover, research has recently focused increasingly on MMR deficiency due to its positive predictive value for the efficacy of immune checkpoints inhibitors (ICKi) in metastatic tumors, regardless of their primary origin. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193004
Publisher Site
http://dx.doi.org/10.1016/j.bulcan.2018.12.008DOI Listing
February 2019
19 Reads
0.635 Impact Factor

[Precision medicine in oncology: Challenges, stakes and new paradigms].

Bull Cancer 2019 Feb 1;106(2):97-104. Epub 2019 Feb 1.

Institut Roche for research & translational medicine, 30, cours de l'île-Seguin, 92650 Boulogne-Billancourt, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.007DOI Listing
February 2019
2 Reads

[Microsatellite instability (MSI): best predictor of effectiveness of immune checkpoint inhibitors (ICKi)? Focus on MSI by Bulletin du Cancer].

Authors:
Thierry André

Bull Cancer 2019 Feb 31;106(2):91-93. Epub 2019 Jan 31.

Hôpital Saint-Antoine, Sorbonne université, service d'oncologie médicale, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.009DOI Listing
February 2019

[Before seasonal influenza, vaccination of cancer patients and healthcare givers].

Bull Cancer 2019 Feb 30;106(2):94-96. Epub 2019 Jan 30.

Centre Oscar-Lambret, service de soins palliatifs, 3, rue Combemale, 59020 Lille cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.006DOI Listing
February 2019

[Editorial of the French Society of Cancer].

Bull Cancer 2019 Jan;106(1)

Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.003DOI Listing
January 2019

[New year, new resolutions? 2019: Some changes in continuity].

Bull Cancer 2019 Jan;106(1):2-3

Université de Nice Sophia-Antipolis, CNRS-Inserm-UNS, institut de biologie Valrose, 06108 Nice cedex 2, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.01.001DOI Listing
January 2019

Traitement par cellules CAR-T : état des lieux de leur utilisation aux États-Unis en 2018.

Authors:
Jordan Gauthier

Bull Cancer 2018 Dec;105 Suppl 2:S214-S217

Fred Hutchinson Cancer Research Center, Seattle, WA, États-Unis. Electronic address:

Car-t Therapy: CURRENT USE IN THE UNITED STATES IN 2018: Treatment with T-cells engineered with chimeric antigen receptors (CAR T-cell therapy) has been a field of intense research in the United States since the 1980s. The recent approval in August 2017 of Kymriah (tisagenlecleucel) opened the door to broader access to CAR T-cell therapy outside of clinical trials. Here, we aim to give the reader a practical summary of the current practices in the US when considering a patient for CAR T-cell therapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193005
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30052-9DOI Listing
December 2018
8 Reads

Rôle du pharmacien hospitalier dans le circuit d’une catégorie de Médicament de Thérapie Innovante : les lymphocytes T exprimant un Récepteur Chimérique à l’Antigène.

Bull Cancer 2018 Dec;105 Suppl 2:S205-S213

Centre Hospitalier Universitaire de Lille, Institut de Pharmacie, 59037 Lille, France; Faculté de pharmacie de Lille, Unité Grita EA7365, 59000 Lille, France.

ROLE OF THE HOSPITAL PHARMACIST IN THE MANAGEMENT OF A CATEGORY OF ADVANCED THERAPY MEDICINAL PRODUCT: CHIMERIC ANTIGEN RECEPTOR T-CELLS: Chimeric Antigen Receptor T-cells (CART) belongs to a new class of medicine, Advanced Therapy Medicinal Product, such as define by the European Regulation 1394/2007, and more exactly to the category of gene therapy medicinal product. Their status of medicine, as well as genetically modified organisms, imposes a particular circuit at hospital while maintaining a way over the Hospital Pharmacy. The manipulation of genetically modified cells is not usual in pharmacy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193005
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30051-7DOI Listing
December 2018
8 Reads

Réglementations applicables aux CAR-T cells : comment les établissements de santé français peuvent-ils s’organiser pour participer à la production et permettre la délivrance de ces immunothérapies innovantes ?

Bull Cancer 2018 Dec;105 Suppl 2:S198-S204

AP-HP, Hôpital Saint-Louis, Unité de Thérapie Cellulaire & Inserm CBT-501, Centre d'Investigations Cliniques en Biothérapies, 75010 Paris, France.

Regulatory Framework For Car-t Cells: HOW CAN FRENCH HEALTHCARE PROVIDERS ADAPT THEIR ORGANIZATION TO REQUIREMENTS FOR MANUFACTURING AND DELIVERY OF THESE INNOVATIVE CELL-BASED MEDICINAL PRODUCTS?: More than five years after the first US publications reporting a significant rate of clinical responses in patients with high-risk or advanced CD19+ lymphoid malignancies, access to treatment with CAR-T Cells at European hospitals in general and at French hospitals in particular remains limited. One - and not the least - hurdle lay in the need to set up a complex and unprecedented organization that complies with European regulations on Advanced Therapy Medicinal Products as well as with national (French) regulations. We here review the organizational framework for two situations: delivery and administration of industry-manufactured CAR-T Cells as well as engineering and distribution of CAR-T Cells produced as investigational drugs to be evaluated in the context of clinical research protocols. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193005
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30050-5DOI Listing
December 2018
6 Reads

Gestion des toxicités des lymphocytes T exprimant un récepteur à l’antigène chimérique (CAR-T cells).

Bull Cancer 2018 Dec;105 Suppl 2:S188-S197

Service d'Hématologie Clinique, CHU Hôtel-Dieu, 44093 Nantes Cedex, France. Electronic address:

Toxicity Management Of Chimeric Antigen Receptor T-cells: Chimeric antigen receptor T-cells (CAR T-cells) represent a very promising treatment for both hematological malignancies and solid tumors. Many clinical trials are currently on-going to establish the role of this emerging therapy. The toxicities observed after CAR T-cells infusion are mostly represented by a cytokine release syndrome and neurological symptoms. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193004
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30049-9DOI Listing
December 2018
8 Reads

Développement des CAR-T dans les tumeurs solides.

Bull Cancer 2018 Dec;105 Suppl 2:S178-S187

INSERM U1052, Centre de Recherche en Cancérologie, 69008 Lyon, France; Cellectis, 75013 Paris, France; Centre Léon Bérard, 69008 Lyon, France; Université Claude Bernard Lyon 1, 69100 Villeurbanne, France. Electronic address:

Development Of Car T-cells In Solid Tumors: CHALLENGES AND PERSPECTIVES: While Chimeric Antigen Receptor (CAR) T-cells have shown outstanding results in some hematologic malignancies, studies in solid tumors are less encouraging with poor response rates. Several factors can account for this lack of efficiency in solid tumors: heterogeneous expression or absence of specific target antigen (and so higher risk of toxicity), immunosuppressive microenvironment, homing and tumoral trafficking issues or lack of CAR T-cell persistence. Different approaches can be considered to overcome these resistance mechanisms: bispecific CARs, use of logic gates, combination with immune checkpoint inhibitors, engineered CAR T-cells resistant to immunosuppressive molecules, addition of chemokines or enzymes, combination with oncolytic virus, intra-tumoral administration, selection of memory T cell subpopulations and development of armored CAR T-cells secreting cytokines such as IL-12, -15 or -18. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193004
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30048-7DOI Listing
December 2018
9 Reads

L’émergence des traitements par cellules CAR-T dans les lymphomes.

Bull Cancer 2018 Dec;105 Suppl 2:S168-S177

Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, 69495 Pierre Bénite cedex, France; Université Claude Bernard Lyon-1, 69100 Villeurbanne, France.

Emerging Therapies Using Car-t Cells In Lymphoma: After the promising results obtained in North American academic centers suggesting the curative potential of these treatments, the development of T cells carrying a chimeric antigen receptor (CAR-T) directed against the CD19 antigen has experienced rapid developments in recent years. Three major trials (each involving about 100 patients with relapsed or refractory aggressive B-cell lymphoma) were conducted and evaluated the efficacy of these treatments (Zuma-1, Juliet and Transcend). Tumor responses are observed in 52% to 82% of patients, with a best complete response (CR) rate of 40% to 58%. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193004
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30047-5DOI Listing
December 2018
9 Reads

Traitement par CAR-T des leucémies aiguës de l'adulte.

Bull Cancer 2018 Dec;105 Suppl 2:S158-S167

Unité d'Hématologie Adolescents et Jeunes Adultes, Hôpital Saint-Louis, 75010 Paris, France; EA-3518, Unité de Recherche Clinique Appliquée à l'Hématologie, Institut Universitaire d'Hématologie, Université Paris Diderot, 75010 Paris, France. Electronic address:

Car-t Treatment Of Acute Leukemia In Adults: The prognosis for acute lymphoblastic leukemia (ALL) in adults remains poor in refractory or relapsed (R/R) situations. Among the immunotherapy strategies that have recently been developed, CAR-T cells (chimeric antigen receptor modified T-cells) represent a major technological and therapeutic advance in the management of adult and pediatric patients with such resistant diseases. The first CAR-T trials targeting the ubiquitous B-cell antigen CD19 showed very encouraging results with complete remission rates of approximately 80%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(19)30046-3DOI Listing
December 2018
7 Reads

CAR-T cells : indications actuelles en pédiatrie et perspectives de développement.

Bull Cancer 2018 Dec;105 Suppl 2:S147-S157

Service d'Hématologie Pédiatrique, Hôpital Universitaire Robert Debré (APHP), 75019 Paris, France; Université Paris Diderot, 75010 Paris, France; EA 3518 Institut Universitaire d'Hématologie, 75010 Paris, France. Electronic address:

Car T Cells: CURRENT INDICATIONS IN CHILDREN AND PERSPECTIVES: Acute lymphoblastic leukemia (ALL) is the first cause of cancer in children. Five-year overall survival is greater than 90% but leukemia remains a major cause of death from cancer in children. A new class of immunotherapy based on a chimeric antigen receptor "CAR" targeting the CD19 on the B leukemic cells and that is transduced in an autologous or allogenic T lymphocyte will allow to transform the prognosis of refractory or relapsed B-ALL. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00074551193004
Publisher Site
http://dx.doi.org/10.1016/S0007-4551(19)30045-1DOI Listing
December 2018
5 Reads

Biologie, concepts et principes des CAR-T cells.

Bull Cancer 2018 Dec;105 Suppl 2:S135-S146

Centre Hospitalo-Universitaire Régional de Besançon, service d'hématologie, UMR1098 INSERM/UBFC/EFS, 25020 Besançon, France.

Car-t Cells: BIOLOGY, CONCEPTS AND PRINCIPLES: The development of new anti-tumor immunotherapy approaches has recently dramatically increased. Progresses made in molecular biology and the development of various genetic manipulation tools allow the "reprogrammation" of T cells in order to make them express a chimeric receptor including the variable part of an immunoglobulin capable of recognizing a tumor antigen along with the expression of molecules involved in T-lymphocyte activation signaling. Genetically modified T-cells, called "CAR (chimeric antigen receptors) -T cells", have yielded impressive clinical results in the treatment of relapsed or refractory lymphoid hematological malignancies after conventional treatments and are in development in solid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(19)30044-XDOI Listing
December 2018
1 Read